Cargando…

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m-2 every 3 weeks as a 1 h infusion without routine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sternberg, C. N., ten Bokkel Huinink, W. W., Smyth, J. F., Bruntsch, V., Dirix, L. Y., Pavlidis, N. A., Franklin, H., Wanders, S., Le Bail, N., Kaye, S. B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033513/ https://www.ncbi.nlm.nih.gov/pubmed/7914427

Ejemplares similares

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
por: Sulkes, A., et al.
Publicado: (1994)

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
por: Cerny, T., et al.
Publicado: (1994)

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
por: Hanauske, A. R., et al.
Publicado: (1996)

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
por: McLeod, H. L., et al.
Publicado: (1996)

Interaction of Docetaxel (“Taxotere”) with Human P‐Glycoprotein
por: Shirakawa, Katsuro, et al.
Publicado: (1999)

Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.
por: Kaplan, S., et al.
Publicado: (1996)

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.
por: Hennequin, C., et al.
Publicado: (1995)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
por: Verweij, J.
Publicado: (1994)

Antitumor Effects of Combining Docetaxel (Taxotere) with the Antivascular Action of Ultrasound Stimulated Microbubbles
por: Goertz, David E., et al.
Publicado: (2012)

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995)

The Effect of Docetaxel (Taxotere(®)) on Human Gastric Cancer Cells Exhibiting Low-Dose Radiation Hypersensitivity
por: Balcer-Kubiczek, Elizabeth K., et al.
Publicado: (2008)

Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial
por: Spielmann, M, et al.
Publicado: (2002)

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998)

Análisis de taxoides (taxus globosa schlech)
por: Ramos Lobato, Nancy Aurelia
Publicado: (1998)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

Physical and chemical stability of Taxotere(®) (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage
por: Hart, M, et al.
Publicado: (2010)

Characterisation of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids.
por: Debal, V., et al.
Publicado: (1994)

Safety and efficacy of single‐agent docetaxel (Taxotere) administered weekly in non‐small cell lung carcinoma patients in Korea: An observational study
por: Lim, Sun Min, et al.
Publicado: (2015)

Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II
por: Kim, Sung-Bae, et al.
Publicado: (2015)

Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery
por: Ojima, Iwao, et al.
Publicado: (2018)

Synthesis and Cytotoxicity of 7,9-O-Linked Macrocyclic C-Seco Taxoids
por: Zhao, Yu, et al.
Publicado: (2019)

Multicellular Tumor Spheroids for Evaluation of Cytotoxicity and Tumor Growth Inhibitory Effects of Nanomedicines In Vitro: A Comparison of Docetaxel-Loaded Block Copolymer Micelles and Taxotere®
por: Mikhail, Andrew S., et al.
Publicado: (2013)

Comparative metabolomic analysis reveals the variations in taxoids and flavonoids among three Taxus species
por: Zhou, Ting, et al.
Publicado: (2019)

Profiling of Taxoid Compounds in Plant Cell Cultures of Different Species of Yew (Taxus spp.)
por: Kochkin, Dmitry V., et al.
Publicado: (2023)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

Chemical Constituents from Streblus taxoides Wood with Their Antibacterial and Antityrosinase Activities Plus in Silico Study
por: Parndaeng, Kedsaraporn, et al.
Publicado: (2023)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
por: de Wit, R., et al.
Publicado: (1998)

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
por: de Wit, R., et al.
Publicado: (1997)

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
por: Tesei, Anna, et al.
Publicado: (2011)

Design, Synthesis, and Biological Evaluations of Tumor-Targeting Dual-Warhead Conjugates for a Taxoid–Camptothecin Combination Chemotherapy
por: Vineberg, Jacob G., et al.
Publicado: (2014)

Multidrug Resistance Reversal Activity of Taxoids from Taxus cuspidate in KB‐C2 and 2780AD Cells
por: Kobayashi, Jun'ichi, et al.
Publicado: (2000)

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
por: Van den Brande, J, et al.
Publicado: (2003)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells
por: Li, Yiwei, et al.
Publicado: (2005)

Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2
por: Boudny, V, et al.
Publicado: (2002)

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response
por: Boniface, Christopher T., et al.
Publicado: (2022)

Taxoid profile in endophytic fungi isolated from Corylus avellana, introduces potential source for the production of Taxol in semi-synthetic approaches
por: Mohammadi Ballakuti, Narjes, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_frkrdvll95jg4b5c1e4amj91up